By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

National Cancer Institute (NCI) 

NCI Public Inquiries Office
Building, 31, Room 10A03
31 Center Drive, MSC 2

Bethesda  Maryland  20892-2580  U.S.A.
Phone: 301-435-3848 Fax:


SEARCH JOBS




Collaborations

Maxygen, Inc. 

Genzyme General 

PanVera LLC 

Panacos Pharmaceuticals Inc.  Panacos has a CRADA with leading scientists at the National Cancer Institute to study the mechanism of HIV maturation inhibitors and to discover new antiviral drugs.





Company News
ZIOPHARM Oncology (ZIOP) Release: Biopharma And Intrexon (XON) Announce Cooperative Research And Development Agreement With The NCI Utilizing Sleeping Beauty System To Generate T Cells Targeting Neoantigens 1/10/2017 10:42:37 AM
Threshold Pharma (THLD) And NCI To Collaborate On Drug Candidate TH-3424 12/19/2016 1:09:55 PM
Syndax Announces Collaboration With The NCI To Develop Entinostat And SNDX-6352 For The Treatment Of Cancer 12/14/2016 7:12:31 AM
Moleculin Biotech (MBRX) Presents Preclinical Data Of Novel Inhibitor Of Glycolysis At 28th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 12/13/2016 10:03:49 AM
Kite Pharma (KITE) Announces Publication Of T-Cell Therapy Targeting Mutant KRAS In Cancer By The NCI In The New England Journal of Medicine 12/12/2016 10:33:13 AM
AACR Receives $1.125 Million NCI Grant To Continue Clinical Trials Workshop 12/12/2016 10:07:05 AM
Ignyta (RXDX) Release: Late-Breaking Oral Plenary Presentation Of A Novel Entrectinib Combination Regimen At The 2016 EORTC-NCI-AACR Annual Meeting 12/2/2016 11:01:32 AM
CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At European Organization for Research and Treatment of Cancer-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 12/2/2016 6:40:58 AM
VAXIMM Presents Preclinical Data On Three Novel Oral T-Cell Cancer Immunotherapies At EORTC-NCI-AACR Symposium 12/1/2016 3:22:07 PM
Ignyta (RXDX) Announces Compelling Phase I/Ib Clinical Data On RXDX-105, Its VEGFR-Sparing RET Inhibitor, At The 2016 EORTC-Ignyta (RXDX)-NCI Annual Meeting 12/1/2016 10:50:12 AM
12345678910...
//-->